PharmaPhobia & What to Do About It: Tom Stossel Attempts to Debunk the Conflict-of-Interest...
Will Tom Stossel's new book title PHARMAPHOBIA, which ends with a section on 'What is to be done,' turn the tide as he hopes it will? This article reviews some of Stossel's main arguments. You be the judge.
The Patients Included Initiative & Pharma: Pharma Should Offer Continuing Patient Education Grants
One of the guidelines of the Patients Included charter requires scholarships for patient to attend medical and pharma industry conferences. But who will pay the way for patients to attend and how will the scholarships be administered? This article discusses that issue and suggests that the pharmaceutical industry, which claims to be 'patient centric,' can play a role by sponsoring Patients Included scholarships similar to how they sponsor physician continuing medical education programs for physicians.
Pharma Marketing News Vol. 14, No. 4: May 2015
Welcome to Vol. 14, Issue No. 4 (MAY 2015) of Pharma Marketing News. Pharma's image is the theme of this issue. Marketing buzzwords, critics claim, erode patient and healthcare professional trust. Pharma phobia is aided and abetted by the conflict-of-interest movement. And patients are demanding to have access inside the tent of health conferences--including pharma marketing conferences--that claim to represent patient interests but do not have patients included.
The Debut of the Chief Patient Officer: Is It Just a Passing Fad or...
This article summarizes the roles of Chief Patient Officers in bringing the patient perspective into their company's work. Sanofi is used as a case study.
DTC Ad Spending Rises From the Grave: Pfizer Leads the Ghoulish Pack
This article presents the data and discusses Pfizer's leading role in the DTC ad resurgence, especially in regard to TV advertising, which accounts for almost 70% of all DTC advertising dollars.
Pharma Marketing News Vol. 14, No. 3: April 2015
Welcome to Vol. 14, Issue No. 3 (APRIL 2015) of Pharma Marketing News. Patient centricity, direct-to-consumer advertising, and key opinion leaders are the focus of this issue. All are related in the sense that each area has seen major changes & shifts in thinking with more to come.
The Consumer Brief Summary: FDA’s New Thinking Regarding Risk Communication
New FDA guidelines jettison the 'traditional approach' to fulfilling the brief summary requirement and replaces it with what the FDA calls the 'Consumer Brief Summary.' This article summarizes the new guidelines and reviews the need for additional guidelines that specifically address the fair balance section of DTC print ads.
The Next FDA Commissioner Will Be… Industry Pundits Think It’s a Shoe-In. Do You?
In a new survey, Pharma Marketing News asks your opinion about who should be the next FDA commissioner.
The survey has been seeded with the candidates mentioned in this article. You can choose one of these or enter your own choice.
Patient Centricity, Transparency, & Pharma’s Reputation: Getting Beyond Lip Service
This article discusses real world examples of patient-centricity in pharmaceutical marketing and the need for more transparency in how pharmaceutical companies partner with patients online.
Pharma Marketing News Vol. 14, No. 2: February 2015
Welcome to Vol. 14, Issue No. 2 (FEBRUARY 2015) of Pharma Marketing News. The FDA is a hot topic in this issue. Specifically, it's new thinking on presenting risk information in direct-to-consumer print ads. Are the new guidelines relevant for online advertising?